跳至主要内容
临床试验/NCT07686939
NCT07686939已完成不适用

Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients: A Prospective Randomized Clinical Study

Taizhou Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Accuracy of CGM (MARD < 15%, ISO compliance, and DTS error grid Zones A+B)

研究概览

简要总结

Poor glycemic control is common in critically ill patients with sepsis and is associated with increased morbidity and mortality; however, achieving safe and effective glucose management in the ICU remains challenging with conventional intermittent monitoring. Continuous glucose monitoring (CGM) offers real-time interstitial glucose readings and has the potential to improve detection of dysglycemic events, enhance adherence to glycemic protocols, and reduce nursing workload. This prospective, randomized controlled trial was designed to evaluate the accuracy, clinical effectiveness, and operational utility of a factory-calibrated CGM system (FreeStyle Libre II) compared with standard blood glucose monitoring (fingerstick, arterial, and venous measurements) in septic ICU patients. The primary outcomes include CGM accuracy against reference methods, protocol adherence rates, time efficiency, and the incidence of hypoglycemic and hyperglycemic events. The findings of this trial will help determine whether CGM can provide a reliable, clinically feasible, and time-saving alternative for glycemic management in this high-risk population, thereby supporting its integration into routine ICU practice and informing future larger-scale studies on long-term outcomes and cost-effectiveness.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years.
  • Confirmed infection accompanied by an increase in Sequential Organ Failure Assessment (SOFA) score of ≥ 2 points.
  • Written informed consent provided by the patient or legally authorized representative.

排除标准

  • Discharge against medical advice or transfer to another facility before study completion, leading to incomplete data.
  • Non-cooperation with study procedures.
  • Contraindications to the application of the flash glucose monitoring sensor (e.g., severe skin disease at insertion site, known allergy to sensor components).

结局指标

主要结局

Accuracy of CGM (MARD < 15%, ISO compliance, and DTS error grid Zones A+B)

时间窗: Throughout the 1-2 week ICU stay

次要结局

  • Protocol Adherence Rate(Throughout the 1-2 week ICU stay)
  • Target Glucose Achievement Rate(Throughout the 1- to 2-week ICU stay.)
  • Hypoglycemia Detection Rate(Throughout the 1- to 2-week ICU stay.)
  • Hyperglycemia Detection Rate(hroughout the 1- to 2-week ICU stay.)
  • Nursing Time per Measurement(Throughout the 1- to 2-week ICU stay.)

研究者

发起方
Taizhou Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Cheng Zheng

Clinical Professor

Taizhou Hospital

研究点 (1)

Loading locations...

相似试验